Threshold Pharmaceuticals : Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma

Press/Media: Press / Media

PeriodNov 17 2014

Media coverage

4

Media coverage

  • TitleThreshold Pharmaceuticals : Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
    Media name/outlet4 Traders
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab … Marketwired
    Media name/outletYahoo! Finance
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma / 64% of Patients Achieved Stable Disease or Tumor Shrinkage on Combination Therapy Following Progression
    Media name/outletFinanzNachrichten.de
    CountryGermany
    Date11/17/14
    PersonsAndrew Brenner
  • TitleThreshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients ...
    Media name/outletEIN News
    CountryUnited States
    Date11/17/14
    PersonsAndrew Brenner